PLEASANTON, Calif., Feb. 28, 2023 /PRNewswire/ -- New research shows a majority of medtech organizations are taking action to advance regulatory affairs, according to the second annual Veeva MedTech Regulatory Benchmark Report. More than half of medtech companies say establishing a single source for regulatory information (62%) and implementing a global and centralized regulatory information management (RIM) system (51%) will be the industry's top focus over the next two years. With the move to modernize RIM underway, medtech leaders are bringing together data, content, and systems for improved insights and time to market.

Data reveals an increased focus on digital systems to harmonize operations globally, with two out of every five companies already selecting digital regulatory technology. This shift toward digital RIM systems highlights the need for greater transparency and collaboration across regional teams to meet evolving regulations and change management requirements.
The report reveals positive changes to regulatory affairs and opportunities for improvement, including:
"With new regulations and increasing supply chain complexity, medtech companies are evaluating paths to more seamless processes so high-quality data can be shared across teams," said Seth Goldenberg, vice president, Veeva MedTech. "This research shows the medtech industry is making progress by advancing regulatory operations for better global visibility, data accuracy, and compliance."
The Veeva MedTech Regulatory Benchmark Report examines the medical device and diagnostic industry's progress toward modernizing regulatory operations. Survey respondents include regulatory affairs professionals from more than 100 medtech organizations around the globe, ranging from enterprise to midsize businesses. See the full annual study which explores how medtech companies manage global compliance and visibility, speed to market, post-market compliance, and modernization.
About Veeva Systems
Veeva (NYSE: VEEV) is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Contact:
Deivis Mercado
Veeva Systems
925-226-8821
This email address is being protected from spambots. You need JavaScript enabled to view it.

| Last Trade: | US$217.05 |
| Daily Change: | 1.58 0.73 |
| Daily Volume: | 1,582,051 |
| Market Cap: | US$35.680B |
December 04, 2025 December 03, 2025 November 24, 2025 November 20, 2025 November 04, 2025 | |

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MOREEnd of content
No more pages to load